Cefoperazone/Sulbactam: Extended coverage with β-lactamase inhibition
Adapted from Lai CC, et al. 2018.
The synergistic in vitro antibacterial activity of the cefoperazone + sulbactam combination results in lower MICs compared with cefoperazone alone for a wide range of pathogens.
Cefoperazone/Sulbactam enhances cefoperazone activity against most MDROs excluding carbapenem-resistant P. aeruginosa, and the activity is greatest at a ratio of 1:2, followed by ratios of 1:1 and 2:1.2
ESBL, extended-spectrum β-lactamase; MDRO, multidrug-resistant organism; MIC, minimum inhibitory concentration.
Please click the Prescribing Information link to view the safety and adverse events information of MAGNEX®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
Please see full Prescribing Information for PRODUCT, including BOXED WARNING.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022